Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway

Cancer Research

Volumn 73, Issue 10, 2013, Pages 3041-3050

  Li, Zhizhong ^a   Zhang, Yunyu ^a   Ramanujan, Krishnan ^a   Ma, Yan ^b   Kirsch, David G ^b   Glass, David J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; HIGH MOBILITY GROUP B2 PROTEIN; INSULIN GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOBLAST; NONHUMAN; ONCOGENE N RAS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GTP PHOSPHOHYDROLASES; HMGA2 PROTEIN; HUMANS; MEMBRANE PROTEINS; MICE; MYOBLASTS; RHABDOMYOSARCOMA, EMBRYONAL; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84877847218     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3947     Document Type: Article

References (36)

1. Bizer LS. Rhabdomyosarcoma. Am J Surg 1980;140:687-91. (Pubitemid 11240777)
2. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am J Pathol 2009;174:550-64.
3. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002;1:97-104.
4. Martinelli S, McDowell HP, Vigne SD, Kokai G, Uccini S, Tartaglia M, et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 2009;48:975-82.
5. Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer cell 2011; 19:177-91.
6. Zhou X, Chada K. HMGI family proteins: Architectural transcription factors in mammalian development and cancer. Keio J Med 1998;47: 73-7. (Pubitemid 128472975)
7. Cleynen I, Van de Ven WJ. The HMGA proteins: A myriad of functions (Review). Int J Oncol 2008;32:289-305. (Pubitemid 351188295)
8. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-71. (Pubitemid 43832192)
9. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation. Science 2007;315: 1576-9. (Pubitemid 46449474)
10. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30. (Pubitemid 46686471)
11. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009; 174:854-68.
12. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010; 1799:48-54.
13. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to- mesenchymal transition. J Biol Chem 2008;283: 33437-46.
14. Li AY, Lin HH, Kuo CY, Shih HM, Wang CC, Yen Y, et al. High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol 2011;31:2605-17.
15. Brants JR, Ayoubi TA, Chada K, Marchal K, Van de Ven WJ, Petit MM. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett 2004;569:277-83. (Pubitemid 38844632)
16. Christiansen J, Kolte AM, Hansen TO, Nielsen FC. IGF2 mRNA-binding protein 2: Biological function and putative role in type 2 diabetes. J Mol Endocrinol 2009;43:187-95.
17. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, WewerUM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-70. (Pubitemid 29046868)
18. Nielsen J, Adolph SK, Rajpert-De Meyts E, Lykke-Andersen J, Koch G, Christiansen J, et al. Nuclear transit of human zipcode-binding protein IMP1. Biochem J 2003;376:383-91. (Pubitemid 38010523)
19. Hansen TV, Hammer NA, Nielsen J, Madsen M, Dalbaeck C, Wewer UM, et al. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol 2004;24:4448-64. (Pubitemid 41071014)
20. Schaeffer V, Hansen KM, Morris DR, Leboeuf RC, Abrass CK. RNAbinding protein IGF2BP2/IMP2 is required for laminin-beta2 mRNA translation and is modulated by glucose concentration. Am J Physiol Renal Physiol 2012;303:F75-82.
21. Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev 2011;25:1159-72.
22. Leeds P, Kren BT, Boylan JM, Betz NA, Steer CJ, Gruppuso PA, et al. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997;14:1279-86. (Pubitemid 27151985)
23. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010;141:129-41.
24. Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res 2010; 70:762-71.
25. Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 1989;49:6324-7. (Pubitemid 20000931)
26. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011;50:397-408.
27. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635-47. (Pubitemid 40343076)
28. Liu J, Luo XJ, Xiong AW, Zhang ZD, Yue S, Zhu MS, et al. MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. J Biol Chem 2010; 285:26599-607.
29. Sharma SV, Settleman J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21:3214-31. (Pubitemid 350277749)
30. Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, et al. An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev Cell. 2012;23:1176-88.
31. Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R, et al. HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res 2007;5:363-72. (Pubitemid 46706998)
32. Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan EM. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol 2005;26:311-7.
33. Zhang L, Liu Y, Hao S, Woda BA, Lu D. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol 2011;35:868-72.
34. Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev 2012;26:1926-44.
35. Kelleher FC, McArthur GA. Targeting NRAS in melanoma. Cancer J 2012;18:132-6.
36. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy inNRAS mutant tumors. PLoS ONE 2009;4:e5717.